Clinical and MRI remission in patients with nonradiographic axial spondyloarthritis who received long-term open-label adalimumab treatment: 3-year results of the ABILITY-1 trial

BACKGROUND: Adalimumab was effective in treating patients with nonradiographic axial spondyloarthritis (nr-axSpA) in the 12-week ABILITY-1 trial. We present long-term efficacy and safety results of adalimumab from the open-label ABILITY-1 extension, including the relationship between clinical and ma...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Heijde, Désirée, Sieper, Joachim, Maksymowych, Walter P., Lambert, Robert G., Chen, Su, Hojnik, Maja, Anderson, Jaclyn K., Pangan, Aileen L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870399/
https://www.ncbi.nlm.nih.gov/pubmed/29587851
http://dx.doi.org/10.1186/s13075-018-1556-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5870399/
https://www.ncbi.nlm.nih.gov/pubmed/29587851
http://dx.doi.org/10.1186/s13075-018-1556-5

Ejemplares similares